Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ LPAM-1 Monoclonal Antibody (DATK32), PE
Rat Monoclonal Antibody
Supplier: Invitrogen™ MLPAM104

Description
LPAM-1 Monoclonal Antibody for Flow
Integrin beta 7 associates with integrin alpha 4 (CD49d) to form the alpha 4 beta 7 integrin LPAM-1, expressed on intraepithelial lymphocytes. It also associates with alpha E (CD103) to form the alpha E beta 7 integrin HML-1, expressed on T cells adjacent to mucosal epithelium and intraepithelial lymphocytes. Ligands for LPAM-1 include VCAM-1 (CD106), MAdCAM-1 and fibronectin, while the ligand of HML-1 is E-cadherin (CD324). Integrin beta 7 plays an important role in the adhesion of leukocytes to endothelial cells promoting the transmigration of leukocytes to extravascular spaces during the inflammatory response.
Specifications
LPAM-1 | |
Monoclonal | |
0.1 mg/mL | |
PBS with <0.1% sodium azide; pH 7.5 | |
P26011, Q00651 | |
Itga4, Itgb7 | |
Mouse LPAM-1. | |
100 μg | |
Primary | |
Mouse | |
Antibody | |
IgG2a κ |
Flow Cytometry | |
DATK32 | |
PE | |
Itgb7 | |
CD49 antigen-like family member D; CD49D; integrin alpha 4; integrin alpha-4; integrin alpha4B; Integrin alpha-IV; integrin beta 7; integrin beta-7; Integrin beta-P; Itga4; Itga4B; Itgb7; LPAM subunit alpha; Ly69; lymphocyte Peyer patch adhesion molecules subunit alpha; M290 IEL antigen; VLA; VLA 4; VLA-4 receptor, alpha 4 subunit; VLA4 subunit alpha; VLA-4 subunit alpha | |
Rat | |
Purified | |
RUO | |
16401, 16421 | |
4°C, store in dark, DO NOT FREEZE! | |
Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction